title: Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections.
abstract: Rifalazil is a benzoxazinorifamycin which inhibits bacterial DNA-dependent RNA polymerase. The benzoxazine ring endows benzoxazinorifamycins with unique physical and chemical characteristics which favor the use of rifalazil and derivatives in treating diseases caused by the obligate intracellular pathogens of the genus chlamydia. Minimal inhibitory concentrations of benzoxazinorifamycins against chlamydia are in the pg/mL range. These compounds have potential as monotherapeutic agents to treat chlamydia-associated disease because they retain activity against chlamydia strains resistant to currently approved rifamycins such as rifampin. A pivotal clinical trial with rifalazil has been initiated for the treatment of peripheral arterial disease. The rationale for this innovative use of rifalazil, including the association of C. pneumoniae in atherosclerotic plaque formation, as well as rifalazil's potency and efficacy against chlamydia in both preclinical and clinical studies, is discussed. Other benzoxazino derivatives may have utility as stand-alone topical antibacterials or combination antibacterials to treat serious Gram-positive infections. None of the benzoxazinorifamycins examined to date induce the cytochrome P450 3A4 enzyme. This is in contrast to currently approved rifamycins which are strong inducers of P450 enzymes, resulting in drug-drug interactions that limit the clinical utility of this drug class.
authors.affiliation: ActivBiotics, Inc., Lexington, Massachusetts 02421, USA. drothstein@activbiotics.com
authors.forename: David M
authors.initials: DM
authors.lastname: Rothstein
authors.forename: John
authors.initials: J
authors.lastname: van Duzer
authors.forename: Andrew
authors.initials: A
authors.lastname: Sternlicht
authors.forename: Steven C
authors.initials: SC
authors.lastname: Gilman
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy / Q000382:microbiology; D002690:Chlamydia Infections / Q000188:drug therapy* / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000382:microbiology; D012293:Rifampin / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012294:Rifamycins / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D012294:Rifamycins; C068980:KRM 1648; D012293:Rifampin